Multiple Myeloma

D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

The CHMP has recommend the approval of subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma.

The CHMP has issued a positive opinion for linvoseltamab in relapsed/refractory multiple myeloma.

Multiple myeloma experts offer their perspectives on the evolution of the treatment landscape over the past 10 years and look towards the future of care.

Step-up dosing with etentamig produced responses and low rates of CRS in relapsed/refractory multiple myeloma.

Isatuximab plus VRd has been approved in Japan for transplant-ineligible, newly diagnosed multiple myeloma.

Panelists comment on recent updates from the International Myeloma Society/ American Society of Hematology (IMS/ASH) 2024 annual meetings, discussing the efficacy of approved bispecific antibodies in relapsed/refractory multiple myeloma (R/R MM), including teclistamab (MajesTEC-1), elranatamab (MagnetisMM-3), and talquetamab (MonumenTAL-1).

The top 5 videos of the week cover insights in prostate cancer, multiple myeloma, RCC, urothelial carcinoma, and LBCL.

Panelists provide a high-level overview of the treatment landscape for later-stage relapsed/refractory multiple myeloma (R/R MM), discussing the latest therapies and emerging treatment options for this patient population.

Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.

Ide-cel proved feasible and effective in boosting response in patients with myeloma with suboptimal response to standard frontline therapy.

The top 5 videos of the week cover insights in plexiform neurofibromas, melanoma, myeloma, leukemia, and LBCL.

Cilta-cel led to rapid and deep MRD negativity in patients with lenalidomide-refractory multiple myeloma.

Janine Joseph, MS, MBA, discusses the effects of resistance training interventions on fatigue and pain levels in patients with multiple myeloma.

P-BCMA-ALLO1 displayed early efficacy and safety data in relapsed/refractory multiple myeloma.